Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

J Studios Introduction My last look at Axsome Therapeutics, Inc. (NASDAQ:AXSM) followed their Q4 2023 eamings report, in which Auvelity (destromethorphan-bupropion), the nsy substan and and ancel and the colorios in revented in the revene of the quarter and ST30. million for helenty pear bayolution, dospital, dospital, dospital, dospital, t market sentiment, but balanced against financial and operational risks." Since the February recommendation, Axsome's stock has remained relatively unchanged. VAL 84.09 A ...